AR040222A1 - Sales farmaceuticas de reboxetina - Google Patents
Sales farmaceuticas de reboxetinaInfo
- Publication number
- AR040222A1 AR040222A1 ARP030102115A ARP030102115A AR040222A1 AR 040222 A1 AR040222 A1 AR 040222A1 AR P030102115 A ARP030102115 A AR P030102115A AR P030102115 A ARP030102115 A AR P030102115A AR 040222 A1 AR040222 A1 AR 040222A1
- Authority
- AR
- Argentina
- Prior art keywords
- reboxetine
- pharmaceutical salts
- enantiomer
- fumarate
- salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 2
- 229960003770 reboxetine Drugs 0.000 title abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 150000003890 succinate salts Chemical class 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- CBQGYUDMJHNJBX-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1OC(C=1C=CC=CC=1)C1OCCNC1 CBQGYUDMJHNJBX-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008196 pharmacological composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077366 | 2002-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040222A1 true AR040222A1 (es) | 2005-03-16 |
Family
ID=29724495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102115A AR040222A1 (es) | 2002-06-17 | 2003-06-13 | Sales farmaceuticas de reboxetina |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20070010517A1 (https=) |
| EP (1) | EP1515959B1 (https=) |
| JP (1) | JP4563172B2 (https=) |
| KR (1) | KR100779786B1 (https=) |
| CN (2) | CN1662511B (https=) |
| AR (1) | AR040222A1 (https=) |
| AT (1) | ATE439354T1 (https=) |
| AU (1) | AU2003227755B2 (https=) |
| BR (1) | BR0311878A (https=) |
| CA (1) | CA2489763C (https=) |
| DE (1) | DE60328787D1 (https=) |
| DK (1) | DK1515959T3 (https=) |
| ES (1) | ES2328472T3 (https=) |
| MX (1) | MXPA04011916A (https=) |
| MY (1) | MY131231A (https=) |
| NO (1) | NO329346B1 (https=) |
| NZ (1) | NZ537023A (https=) |
| PE (1) | PE20040565A1 (https=) |
| PL (1) | PL375211A1 (https=) |
| RU (1) | RU2286341C2 (https=) |
| TW (1) | TWI267510B (https=) |
| WO (1) | WO2003106441A1 (https=) |
| ZA (1) | ZA200409624B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319793D0 (en) | 2003-08-22 | 2003-09-24 | Lilly Co Eli | Pyridinylmorpholine derivatives |
| WO2005082869A1 (en) * | 2004-02-20 | 2005-09-09 | Pharmacia & Upjohn Company Llc | Method for the preparation of aryl ethers |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20190185438A1 (en) * | 2016-12-06 | 2019-06-20 | Tonix Pharmaceuticals Holding Corp. | Salts and polymorphs of esreboxetine |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2167407B (en) * | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
| AU9214498A (en) * | 1997-09-23 | 1999-04-12 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
| UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
| IT1305322B1 (it) * | 1998-04-23 | 2001-05-04 | Pharmacia & Upjohn Spa | Uso di reboxetina per il trattamento di disturbi nervosi |
| US6465458B1 (en) * | 1999-07-01 | 2002-10-15 | Pharmacia & Upjohn Company | Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor |
-
2003
- 2003-06-04 CN CN038139839A patent/CN1662511B/zh not_active Expired - Fee Related
- 2003-06-04 CA CA002489763A patent/CA2489763C/en not_active Expired - Fee Related
- 2003-06-04 MX MXPA04011916A patent/MXPA04011916A/es active IP Right Grant
- 2003-06-04 PL PL03375211A patent/PL375211A1/xx not_active Application Discontinuation
- 2003-06-04 ES ES03725195T patent/ES2328472T3/es not_active Expired - Lifetime
- 2003-06-04 RU RU2005100846/04A patent/RU2286341C2/ru not_active IP Right Cessation
- 2003-06-04 DE DE60328787T patent/DE60328787D1/de not_active Expired - Lifetime
- 2003-06-04 CN CNA200810093308XA patent/CN101298440A/zh active Pending
- 2003-06-04 DK DK03725195T patent/DK1515959T3/da active
- 2003-06-04 AU AU2003227755A patent/AU2003227755B2/en not_active Ceased
- 2003-06-04 NZ NZ537023A patent/NZ537023A/en unknown
- 2003-06-04 WO PCT/EP2003/005261 patent/WO2003106441A1/en not_active Ceased
- 2003-06-04 AT AT03725195T patent/ATE439354T1/de not_active IP Right Cessation
- 2003-06-04 KR KR1020047020412A patent/KR100779786B1/ko not_active Expired - Fee Related
- 2003-06-04 EP EP03725195A patent/EP1515959B1/en not_active Expired - Lifetime
- 2003-06-04 US US10/588,808 patent/US20070010517A1/en not_active Abandoned
- 2003-06-04 BR BR0311878-9A patent/BR0311878A/pt not_active IP Right Cessation
- 2003-06-04 JP JP2004513273A patent/JP4563172B2/ja not_active Expired - Fee Related
- 2003-06-11 TW TW092115889A patent/TWI267510B/zh not_active IP Right Cessation
- 2003-06-11 MY MYPI20032183A patent/MY131231A/en unknown
- 2003-06-13 AR ARP030102115A patent/AR040222A1/es unknown
- 2003-06-17 PE PE2003000594A patent/PE20040565A1/es not_active Application Discontinuation
-
2004
- 2004-11-29 ZA ZA200409624A patent/ZA200409624B/xx unknown
-
2005
- 2005-01-12 NO NO20050183A patent/NO329346B1/no not_active IP Right Cessation
-
2009
- 2009-05-21 US US12/469,780 patent/US20090291953A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
| CR7583A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
| PE20020722A1 (es) | Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano | |
| EA200200117A1 (ru) | Применение ингибиторов моноаминоксидазы для производства лекарств, предназначенных для лечения ожирения | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| MX9700358A (es) | Proceso par a la sintesis de sulfoxidos substituidos. | |
| GT200200272A (es) | Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino] quinazolin-6-il} alil)acetamidayprocedimiento para la produccion | |
| AR003476A1 (es) | Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol | |
| ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| CR7576A (es) | Nuevas sales de perindopril y composiciones farmaceuticas que las contienen | |
| DE59608698D1 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| ATE332894T1 (de) | Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe | |
| AR040222A1 (es) | Sales farmaceuticas de reboxetina | |
| BRPI0408689A (pt) | derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor | |
| DE602004020488D1 (de) | Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen | |
| TR200101970T2 (tr) | Solunum yollarì hastalìklarìnìn tedavisinde matriks metaloproteaz inhibitrleri olarak ikameli 4-biarilbutirik ve 5-biarilpentanoik asit trevlerinin kullanìlmasì | |
| BRPI0414781A (pt) | aminoácidos com afinidade para a proteìna (alfa)2(delta) | |
| PE20020845A1 (es) | Derivados de o -amino-n-hidroxi-acetamida | |
| BR9911679A (pt) | Sais de paroxetina | |
| AR006281A1 (es) | Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares | |
| UY27324A1 (es) | Nuevas sales de napsilato i | |
| ATE432710T1 (de) | Pharmazeutische zusammensetzungen, die diaminooxidase enthalten | |
| PE20030277A1 (es) | Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa | |
| AR023788A1 (es) | Modificacion amorfa de torasemida | |
| SE0201662D0 (sv) | Pharmaceutical combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |